Literature DB >> 23149337

Gs-coupled adenosine receptors differentially limit antigen-induced mast cell activation.

Xiaoyang Hua1, Kelly D Chason, Corey Jania, Tatiana Acosta, Catherine Ledent, Stephen L Tilley.   

Abstract

Mast cell activation results in the immediate release of proinflammatory mediators prestored in cytoplasmic granules, as well as initiation of lipid mediator production and cytokine synthesis by these resident tissue leukocytes. Allergen-induced mast cell activation is central to the pathogenesis of asthma and other allergic diseases. Presently, most pharmacological agents for the treatment of allergic disease target receptors for inflammatory mediators. Many of these mediators, such as histamine, are released by mast cells. Targeting pathways that limit antigen-induced mast cell activation may have greater therapeutic efficacy by inhibiting the synthesis and release of many proinflammatory mediators produced in the mast cell. In vitro studies using cultured human and mouse mast cells, and studies of mice lacking A(2B) receptors, suggest that adenosine receptors, specifically the G(s)-coupled A(2A) and A(2B) receptors, might provide such a target. Here, using a panel of mice lacking various combinations of adenosine receptors, and mast cells derived from these animals, we show that adenosine receptor agonists provide an effective means of inhibition of mast cell degranulation and induction of cytokine production both in vitro and in vivo. We identify A(2B) as the primary receptor limiting mast cell degranulation, whereas the combined activity of A(2A) and A(2B) is required for the inhibition of cytokine synthesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23149337      PMCID: PMC3558828          DOI: 10.1124/jpet.112.198978

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  68 in total

Review 1.  Structure and function of adenosine receptors and their genes.

Authors:  B B Fredholm; G Arslan; L Halldner; B Kull; G Schulte; W Wasserman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-11       Impact factor: 3.000

Review 2.  Mast cells as "tunable" effector and immunoregulatory cells: recent advances.

Authors:  Stephen J Galli; Janet Kalesnikoff; Michele A Grimbaldeston; Adrian M Piliponsky; Cara M M Williams; Mindy Tsai
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

Review 3.  Phosphodiesterase isozymes: molecular targets for novel antiasthma agents.

Authors:  T J Torphy
Journal:  Am J Respir Crit Care Med       Date:  1998-02       Impact factor: 21.405

4.  Activation of adenosine A2 alpha receptors inhibits mast cell degranulation and mast cell-dependent vasoconstriction.

Authors:  M S Fenster; R K Shepherd; J Linden; B R Duling
Journal:  Microcirculation       Date:  2000-04       Impact factor: 2.628

5.  Adenosine-mediated mast cell degranulation in adenosine deaminase-deficient mice.

Authors:  H Zhong; J L Chunn; J B Volmer; J R Fozard; M R Blackburn
Journal:  J Pharmacol Exp Ther       Date:  2001-08       Impact factor: 4.030

6.  Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells.

Authors:  C A Salvatore; S L Tilley; A M Latour; D S Fletcher; B H Koller; M A Jacobson
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

7.  Adenosine and inosine increase cutaneous vasopermeability by activating A(3) receptors on mast cells.

Authors:  S L Tilley; V A Wagoner; C A Salvatore; M A Jacobson; B H Koller
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

Review 8.  New insights into adenosine-receptor-mediated immunosuppression and the role of adenosine in causing the immunodeficiency associated with adenosine deaminase deficiency.

Authors:  Michael S Hershfield
Journal:  Eur J Immunol       Date:  2005-01       Impact factor: 5.532

9.  Adenosine and selective A(2A) receptor agonists reduce ischemia/reperfusion injury of rat liver mainly by inhibiting leukocyte activation.

Authors:  N Harada; K Okajima; K Murakami; S Usune; C Sato; K Ohshima; T Katsuragi
Journal:  J Pharmacol Exp Ther       Date:  2000-09       Impact factor: 4.030

Review 10.  Regulation of human mast cell and basophil function by cAMP.

Authors:  M C Weston; P T Peachell
Journal:  Gen Pharmacol       Date:  1998-11
View more
  4 in total

1.  The role of activated adenosine receptors in degranulation of human LAD2 mast cells.

Authors:  Chi Ting Leung; Ang Li; Juni Banerjee; Zhan-Guo Gao; Taku Kambayashi; Kenneth A Jacobson; Mortimer M Civan
Journal:  Purinergic Signal       Date:  2014-03-05       Impact factor: 3.765

2.  Adenosine/A2B Receptor Signaling Ameliorates the Effects of Aging and Counteracts Obesity.

Authors:  Thorsten Gnad; Gemma Navarro; Minna Lahesmaa; Laia Reverte-Salisa; Francesca Copperi; Arnau Cordomi; Jennifer Naumann; Aileen Hochhäuser; Saskia Haufs-Brusberg; Daniela Wenzel; Frank Suhr; Naja Zenius Jespersen; Camilla Scheele; Volodymyr Tsvilovskyy; Christian Brinkmann; Joern Rittweger; Christian Dani; Mathias Kranz; Winnie Deuther-Conrad; Holger K Eltzschig; Tarja Niemi; Markku Taittonen; Peter Brust; Pirjo Nuutila; Leonardo Pardo; Bernd K Fleischmann; Matthias Blüher; Rafael Franco; Wilhelm Bloch; Kirsi A Virtanen; Alexander Pfeifer
Journal:  Cell Metab       Date:  2020-06-25       Impact factor: 27.287

Review 3.  Purinergic signalling and immune cells.

Authors:  Geoffrey Burnstock; Jean-Marie Boeynaems
Journal:  Purinergic Signal       Date:  2014-10-29       Impact factor: 3.765

Review 4.  Purinergic Signaling in Mast Cell Degranulation and Asthma.

Authors:  Zhan-Guo Gao; Kenneth A Jacobson
Journal:  Front Pharmacol       Date:  2017-12-22       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.